Sold as Pamine, Pamine Forte. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 15, 2026, FDA lists 6 applications for Methscopolamine Bromide (sold as Pamine, Pamine Forte), first approved Apr 9, 1953, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Methscopolamine Bromide | Part D | $591K | -11% | 1,435 |
| Apr 9, 1953 | Pamine, Pamine ForteNDA 8848 ยท New molecular entity | Fougera | 11 | Discontinued |
| Oct 18, 1976 | Methscopolamine BromideANDA 80970 | Pvt Form | 0 | Discontinued |
| Dec 28, 2006 | Methscopolamine BromideANDA 40624 | Chartwell Rx | 1 | Discontinued |
| Dec 6, 2011 | Methscopolamine BromideANDA 40642 | Breckenridge Pharm | 0 | Marketed |
| Sep 24, 2012 | Methscopolamine BromideANDA 200602 | Unichem | 1 | Marketed |
| Feb 1, 2024 | Methscopolamine BromideANDA 216786 | Ne Rx Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
